Current Research Studies (Volunteers Needed)

If you are interested in participating in a clinical trial, please contact the research coordinator listed for that particular clinical trial or complete the Intake Form to the left.

The Intake Form will be forwarded to the program coordinator and you will be contacted by the appropriate person.

A 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment

Purpose:  The purpose of this study is to evaluate the effectiveness, safety, and tolerability of an investigational drug in people with difficulty walking caused by multiple sclerosis (MS).  Participants will receive the investigational drug and assessments over a period of about 5 months.

To participate, you must:

  • Have a Diagnosis of Multiple Sclerosis
  • Be 18 - 70 years of age
  • Able to Walk with or without assistance (cane or walker)

Contact: Michelle Tidwell, RN, BSN, CCRP (404) 367-1317 or

Study to Determine Reliability of Accelerometer based Mechanomyography as a Measure of Muscle Endurance in People with Multiple Sclerosis [746]

Purpose: The purpose of this study is to evaluate how accurately investigators can measure muscle endurance with a novel device using electrical stimulation. Ultimately, this information will be used to measure the effectiveness of different exercises for improving how well a muscle works in people with Multiple Sclerosis (MS). Participants will be asked to attend 2 testing sessions at the Shepherd Center. They must be over 18 years old and cannot have any injury to their legs in the past 3 months. In participants diagnosed with MS, they cannot have had a diagnosed relapse in the past month.

To participate, you must:

  • Be 18 Years or Older
  • Not have any current (in past 12 weeks) musculoskeletal injury to either leg

Contact: Joy Williams (404) 603-4248 or

Pilot Study to Explore the Effectiveness of FES Lower Extremity Cycling to Improve Function in People with Multiple Sclerosis [670]

Purpose: The purpose of this study is to evaluate the effectiveness of FES cycling to improve function in people with MS. We aim to evaluate if this intervention can improve walking in people with MS who are already walking but limited in how far and how long they can walk, or need an assistive device, such as a cane, walker or wheelchair. For people with MS who primarily use a wheelchair for community mobility, we aim to evaluate if FES cycling will improve their feelings of well-being and any areas of function. For all participants we will evaluate response to up to four protocols of FES cycling to determine safety and potential efficacy for decreasing symptoms and improving function.

Contact: Marina Moldavskiy  (404) 350-7655 or

Validation of a Fall Prevention Program Among Non-Ambulatory Wheeled Mobility Device Users with Multiple Sclerosis [733]

Purpose:  The purpose of this project is to evaluate a fall management program for people with MS. The goal of the program is to decrease the number of falls in people with MS who use a wheelchair or scooter and help them know what to do after a fall. The fall management program will teach each participant how to transfer (move from a wheelchair/scooter to another surface, such as a bed or chair) and to safely manipulate a wheelchair without falling. If they use a cane, crutch or walker, they will learn how to manage it safely during transfers and wheelchair mobility. They will be given strategies to help them recover from a fall. Finally, participants will learn exercises to improve their sitting balance, and about their fall risk and things in their environment that increase the risk of falls.

To participate, you must:

  • Diagnosis of Multiple Sclerosis
  • > 18 years old
  • Mainly use a wheelchair or scooter for mobility
  • Be able to transfer with moderate assistance or less
  • Have at least 1 fall in the past 12 months
  • Be able to sit upright for at least 1 hour

Contact Marina Moldavskiy  (404) 350-7655 or

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

Biogen Protocol Number: 215MS202

Purpose: This is approximately an 18 month study for patients with Relapsing Remitting Multiple Sclerosis or new onset of Secondary Progressive Multiple Sclerosis to evaluate the safety and efficacy of an IV therapy given every 4 weeks in addition to the Disease Modifying Therapy currently prescribed.

To participate, you must:

  • 18-58 years old with a diagnosis of RRMS or new onset of SPMS
  • Experienced the first MS symptom within the previous 20 years
  • On a stable Disease Modifying Therapy for at least 6 months
  • Able to walk without assistance or with an assistive device on one side such as a cane

Contact:  Ashley Howard,RN,BSN  (404) 367-1279 or